Developing broadly reactive HIV-1/AIDS vaccines: A review of polyvalent and centralized HIV-1 vaccines

Current Pharmaceutical Design

Volumn 13, Issue 19, 2007, Pages 1957-1964

  McBurney, Sean P ^a   Ross, Ted M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Consensus; HIV 1 AIDS; Polyvalent; Vaccines; Viral diversity

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; PNEUMOCOCCUS VACCINE; POL PROTEIN; POLIOMYELITIS VACCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSACTIVATOR PROTEIN; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN RECOGNITION; CELLULAR IMMUNITY; CLADISTICS; CLINICAL TRIAL; CONSENSUS SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOREACTIVITY; MORTALITY; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; VACCINIA; VIRAL GENE DELIVERY SYSTEM; VIRUS ISOLATION;

AIDS VACCINES; ANIMALS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; TECHNOLOGY, PHARMACEUTICAL; VACCINES, SUBUNIT;

EID: 34447262868     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039841     Document Type: Review

References (52)

1. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288(5472): 1789-96.
2. UNAIDS. AIDS epidemic update: December 2005: Joint United Nations Programme on HIV/AIDS and World Health Organization; December 2005.
3. Colson AE, Sax PE. Primary HIV-1 infection: Pathogenesis; epidemiology and clinical manifestations. December 2005 [cited 2006 3/6/2006]; Available from: http://www.uptodateonline.com/utd/content/ topic.do?topicKey=hiv_infe/8031&view=print
4. Bartlett JG. Initial antiretroviral therapy for HIV infection. 2006 January 19, [cited 2006 March 6, 2006]; Available from: http://www.uptodateonline.com/utd/content/topic.do?topicKey=hiv_infe/ 22857&view=print
5. Principles of Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses. Second ed. Washington, D.C.: ASM Press 2004.
6. Bukrinskaya AG. HIV-1 assembly and maturation. Arch Virol 2004; 149(6): 1067.
7. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, et al. Reference Guide to HIV-1 Classification. 1999.
8. Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002; 2(8): 461-71.
9. The Circulating Recombinant Forms (CRFs). HIV Sequence Database 2005.
10. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355(6362): 728.
11. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73(5): 4009-18.
12. Slobod K, Coleclough C, Bonsignori M, Brown SA, Zhan X, Surman S, et al. HIV vaccine rationale, design and testing. Curr HIV Res 2005; 3(2): 107-12.
13. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296(5577): 2354-60.
14. Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, et al. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine 2001; 20(5-6): 813.
15. Nehete PN, Nehete BP, Manuri P, Hill L, Palmer JL, Sastry KJ. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Vaccine 2005; 23(17-18): 2154.
16. Brave A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005; 12(6): 1197.
17. Kong W-P, Huang Y, Yang Z-Y, Chakrabarti BK, Moodie Z, Nabel GJ. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003; 77(23): 12764-72.
18. Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002; 302(1): 44.
19. Rollman E, Hinkula J, Arteaga J, Zuber B, Kjerrstrom A, Liu M, et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther 2004; 11(14): 1146-54.
20. Shinoda K, Xin K-Q, Jounai N, Kojima Y, Tamura Y, Okada E, et al. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice. Vaccine 2004; 22(27-28): 3676.
21. Lemiale F, Brand D, Lebigot S, Verrier B, Buzelay L, Brunet S, et al. Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: A comparative study using multivalent vaccine approaches. J Acquir Immune Defic Syndr 2001; 26(5): 413-22.
22. Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ, et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004; 23(2): 106.
23. Pal R, Yu Q, Wang S, Kalyanaraman VS, Nair BC, Hudacik L, et al. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 2006; 24(8): 1225.
24. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006; 346(1): 151.
25. Chakrabarti BK, Ling X, Yang Z-Y, Montefiori DC, Panet A, Kong W-P, et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 2005; 23(26): 3434.
26. Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 2001; 75(5): 2224-34.
27. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005; 34(5-6): 226-36.
28. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology. In Press, Corrected Proof.
29. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005; 79(5): 2956-63.
30. Hamano T, Sawanpanyalert P, Yanai H, Piyaworawong S, Hara T, Sapsutthipas S, et al. Determination of HIV type 1 CRF01Æ gag p17 and env-V3 consensus sequences for HIV/AIDS vaccine design. AIDS Res Hum Retroviruses 2004; 20(3): 337-40.
31. Doria-Rose NA, Learn GH, Rodrigo AG, Nickle DC, Li F, Mahalanabis M, et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 2005; 79(17): 11214-24.
32. Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, Ranasinghe C, et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005; 23(38): 4647.
33. Pamungkas J, Rose RD, Iskandriati D, Noviana R, Paramastri Y, Dale CJ, et al. Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and fowlpox virus boost HIV type 1 vaccine regimens in macaques. AIDS Res Hum Retroviruses 2005; 21(4): 292-300.
34. Cruz LJ, Iglesias E, Aguilar JC, Cabrales A, Reyes O, Andreu D. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1. Bioconjug Chem 2004; 15(5): 1110-7.
35. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, et al. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods 2004; 34(4): 476.
36. De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005; 23(17-18): 2136.
37. Williamson C, Morris L, Maughan MF, Ping L-H, Dryga SA, Thomas R, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 2003; 19(2): 133-44.
38. van Harmelen JH, Shephard E, Thomas R, Hanke T, Williamson A-L, Williamson C. Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine 2003; 21(27-30): 4380.
39. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W, et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 2006; 87(2): 399-410.
40. Hanke T, McMichael AJ, Mwau M, Wee EGT, Ceberej I, Patel S, et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 2002; 20(15): 1995.
41. Wee EGT, Patel S, McMichael AJ, Hanke T. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 2002; 83(1): 75-80.
42. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EGT, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85(4): 911-9.
43. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24(4): 417.
44. Nkolola J, Wee EG-T, Im E-J, Jewell CP, Chen N, Xu X-N, et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 2004; 11(13): 1069-80.
45. Scriba TJ, zur Megede J, Glashoff RH, Treurnicht FK, Barnett SW, van Rensburg EJ. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine 2005; 23(9): 1158.
46. Krohn K, Stanescu I, Blazevic V, Vesikari T, Ranki A, Ustav M. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes Infect 2005; 7(14): 1405.
47. Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, et al. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol 2005; 18(4): 678-88.
48. Gao F, Weaver EA, Lu Z, Li Y, Liao H-X, Ma B, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 2005; 79(2): 1154-63.
49. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79(16): 10108-25.
50. Bourinbaiar AS, Root-Bernstein RS, Abulafia-Lapid R, Rytik PG, Kanev AN, Jirathitikal V, et al. Therapeutic AIDS vaccines. Curr Pharm Des 2006; 12(16): 2017-30.
51. Howett MK, Kuhl JP. Microbicides for prevention of transmission of sexually transmitted diseases. Curr Pharm Des 2005; 11(29): 3731-46.
52. Spearman P. Current progress in the development of HIV vaccines. Curr Pharm Des 2006; 12(9): 1147-67.